Barclays PLC grew its holdings in shares of Sutro Biopharma, Inc. (NASDAQ:STRO – Free Report) by 385.3% during the third quarter, Holdings Channel.com reports. The institutional investor owned 273,019 shares of the company’s stock after purchasing an additional 216,757 shares during the quarter. Barclays PLC’s holdings in Sutro Biopharma were worth $944,000 at the end of the most recent quarter.
Several other large investors also recently modified their holdings of STRO. Geode Capital Management LLC lifted its position in shares of Sutro Biopharma by 7.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,856,956 shares of the company’s stock valued at $6,426,000 after acquiring an additional 132,015 shares during the period. XTX Topco Ltd increased its stake in Sutro Biopharma by 222.0% in the third quarter. XTX Topco Ltd now owns 104,200 shares of the company’s stock valued at $361,000 after purchasing an additional 71,844 shares in the last quarter. Jane Street Group LLC raised its holdings in shares of Sutro Biopharma by 30.7% during the third quarter. Jane Street Group LLC now owns 108,192 shares of the company’s stock valued at $374,000 after purchasing an additional 25,416 shares during the period. State Street Corp boosted its position in shares of Sutro Biopharma by 5.2% during the 3rd quarter. State Street Corp now owns 1,647,162 shares of the company’s stock worth $5,699,000 after purchasing an additional 81,855 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its stake in shares of Sutro Biopharma by 1,195.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 82,524 shares of the company’s stock valued at $286,000 after buying an additional 76,152 shares during the period. Institutional investors and hedge funds own 96.99% of the company’s stock.
Sutro Biopharma Price Performance
STRO opened at $1.72 on Wednesday. Sutro Biopharma, Inc. has a 1 year low of $1.67 and a 1 year high of $6.13. The company has a market capitalization of $141.83 million, a price-to-earnings ratio of -1.07 and a beta of 1.15. The firm’s fifty day moving average price is $2.56 and its two-hundred day moving average price is $3.37.
Analyst Upgrades and Downgrades
Check Out Our Latest Stock Analysis on Sutro Biopharma
Sutro Biopharma Company Profile
Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.
Featured Stories
- Five stocks we like better than Sutro Biopharma
- Insider Trading – What You Need to Know
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- Do ETFs Pay Dividends? What You Need to Know
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Want to see what other hedge funds are holding STRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sutro Biopharma, Inc. (NASDAQ:STRO – Free Report).
Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.